Objectives To review clinical validation or implementation studies of maternal blood cell‐free
(cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 …

Objective To review clinical validation or implementation studies of maternal blood cell‐free
(cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 …

Disclaimer: This statement is designed primarily as an educational resource for clinicians to
help them provide quality medical services. Adherence to this statement is completely …

Background Cell-free DNA (cfDNA) testing for fetal trisomy is highly effective among high-
risk women. However, there have been few direct, well-powered studies comparing cfDNA …

Impressive progress has been made in the field of Next Generation Sequencing (NGS).
Through advancements in the fields of molecular biology and technical engineering …

Objective To measure test accuracy of non-invasive prenatal testing (NIPT) for Down,
Edwards and Patau syndromes using cell-free fetal DNA and identify factors affecting …

Background In high-risk pregnant women, noninvasive prenatal testing with the use of
massively parallel sequencing of maternal plasma cell-free DNA (cfDNA testing) accurately …

Sporadic miscarriage is the most common complication of early pregnancy. Two or three
consecutive pregnancy losses is a less common phenomenon, and this is considered a …

Noninvasive prenatal genetic testing (NIPT) is an advance in the detection of fetal
chromosomal aneuploidies that analyzes cell-free fetal DNA in the blood of a pregnant …

Objectives To report the clinical performance of massively parallel sequencing‐based non‐
invasive prenatal testing (NIPT) in detecting trisomies 21, 18 and 13 in over 140 000 clinical …